• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Rogers Corporation

Rogers Corporation

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris

    FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris

  2. Global Silicone Elastomers Market Analysis 2016 - Forecast to 2022 - Research and Markets

    Global Silicone Elastomers Market Analysis 2016 - Forecast to 2022 - Research and Markets

  3. Phase III APHINITY Study Shows Genentech’s Perjeta® Regimen Helped People with an Aggressive Type of Early Breast Cancer Live Longer Without Their Disease Returning Compared to Herceptin® and ...

    Phase III APHINITY Study Shows Genentech’s Perjeta® Regimen Helped People with an Aggressive Type of Early Breast Cancer Live Longer Without Their Disease Returning Compared to Herceptin® and Chemotherapy

  4. One-Stop Shopping for Exposure to International Stocks

    This iShares’ ETF has appeal, but investors don't have to go much further afield to find more-compelling options.

  5. New Cancer Drugs: First Movers Will Win

    First movers, including Bristol-Myers, and firms that can aggregate a portfolio of immuno-oncology therapies will be positioned well.

  6. Wide-Moat Funds That Fly Under the Radar

    These quality funds with smaller asset bases have portfolios built around solid companies.

  7. Funds Betting on Big Pharma

    Large drugmakers are out of favor, but some good funds are banking on a rebound.

12

©2017 Morningstar Advisor. All right reserved.